News
SABSW
--
0.00%
--
BRIEF-SAB Biotherapeutics Reports Q1 EPS Of $0.02
reuters.com · 05/12 20:23
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated...
GlobeNewswire · 05/12 20:15
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26, 2022. As part of the conference, the company’s manag...
GlobeNewswire · 05/12 13:42
Shareholders in SAB Biotherapeutics (NASDAQ:SABS) are in the red if they invested a year ago
As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...
Simply Wall St. · 05/05 12:34
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibo...
GlobeNewswire · 04/05 10:00
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of...
GlobeNewswire · 03/29 20:30
BRIEF-SAB Biotherapeutics Announces Publication Of Nonclinical Data Demonstrating SAB-185 Has High Potency For Effectively Neutralizing Circulating And Emerging Sars-Cov-2 Variants
reuters.com · 03/02 14:22
BRIEF-Sab Biotherapeutics Reports NIH Is Discontinuing Phase 3 Activ-2 Trial Assessing Sab-185
reuters.com · 03/02 12:31
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed convalescent plasma Findings published...
GlobeNewswire · 03/02 00:30
BRIEF-Sab Biotherapeutics Announces Update To The Phase 3 Nih Activ-2 Trial Design Evaluating Sab-185 For Treatment Of Covid-19
reuters.com · 02/25 12:39
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immuno...
GlobeNewswire · 02/25 11:00
How Much Of SAB Biotherapeutics, Inc. (NASDAQ:SABS) Do Insiders Own?
Every investor in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 02/09 13:16
BRIEF-Sab Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating Sab-185 Met Criteria For Advancement To Phase 3 In Nih Activ-2 Trial For Treatment Of Covid-19
reuters.com · 01/24 12:53
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding ...
GlobeNewswire · 01/24 11:00
First PREMIER Bank Buys SAB Biotherapeutics Inc, Amplify Transformational Data Sharing ETF, 3M ...
Investment company First PREMIER Bank (Current Portfolio) buys SAB Biotherapeutics Inc, Amplify Transformational Data Sharing ETF, 3M Co, Global X Lithium & Battery Tech ETF, BHP Group, sells , iShares 0-5 Year TIPS Bond ETF, iShares Core 1-5 Year USD Bond...
GuruFocus.com · 01/19 22:38
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical resul...
GlobeNewswire · 12/01/2021 12:00
BRIEF-Sab Biotherapeutics Reports Q3 Financial Results
reuters.com · 11/22/2021 12:05
Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics
Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Bus...
PR Newswire · 10/21/2021 11:00
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
SIOUX FALLS, S.D., October 06, 2021--SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
Business Wire · 10/06/2021 11:00
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
SIOUX FALLS, S.D., October 04, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human d...
Business Wire · 10/04/2021 11:00
Webull provides a variety of real-time SABSW stock news. You can receive the latest news about SAB BIOTHERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About SABSW
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.